GeneThera Inc. (OTCMKTS:GTHR) soared 325% no news. However, recently, the company announced incorporating a subsidiary, GeneThera Robotics Ltd., in the UK. The majority-owned subsidiary will be responsible for International UK operations, and Alex Baglietto has been appointed to be the subsidiary’s managing director.
The establishment is the first step of a network of Labs that will build the infrastructure for the Zoonotic Infectious Diseases Alert Shield (ZIDAS). Notably, ZIDAS is a network created in Molecular AI and Robotic technology (MORAP) based on creating two lab settings. First, they will build a mobile lab unit to test wastewater for the presence of SARS-CoV-2.
Evidence suggests that SARS-CoV2 might be present in wastewater, thus indicating that wastewater can be a source of data on assessing risk. Wastewater testing can be used in monitoring outbreaks of SARS-CoV-2 in communities, thus helping in early intervention. In addition, GeneThera has developed the MORAP platform to tests zoonotic diseases. MORAP can process several samples daily.With these developments, GTHR is a stock to watch.
On Monday, GTHR stock soared 325% at $0.0895 with more than 4.18 million shares, compared to its average volume of 27K shares. The stock had moved within a range of $0.0250 – 0.1388 after opening the trade at $0.025.
